Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
August 02, 2021 16:05 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial...
Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations
July 15, 2021 16:05 ET
|
Corvus Pharmaceuticals, Inc.
Mupadolimab Phase 1/1b oncology clinical trial continues, with a focus on leveraging B cell activation and enhancement of anti-viral antibodies in an expansion cohort for patients with HPV+ (human...
Corvus Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
May 25, 2021 16:05 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the Jefferies...
Corvus Pharmaceuticals Completes Sale of $10 Million Through Its ATM Program
May 05, 2021 09:00 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has completed the sale of...
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results
April 29, 2021 16:05 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported...
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
March 25, 2021 08:30 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported...
Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences
March 05, 2021 08:30 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company’s management will...
Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock
February 17, 2021 16:10 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the completion of its previously...
Corvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
February 12, 2021 09:00 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public...
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock
February 11, 2021 16:01 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten...